Pre-Phase III approval possible? EMA's faster adaptive licensing for drugs ready for testing
This article was originally published in SRA
Executive Summary
The adaptive drug licensing procedure that the European Medicines Agency had announced it was contemplating as far back as early 2011 is finally ready for use by companies that wish to test the procedure, Guido Rasi, the EMA's executive director has told Scrip Regulatory Affairs1.